CETN2

Across TCGA pan-cancer cohorts, CETN2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CETN2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where CETN2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CETN2 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

COAD, HNSC, and CCRCC are the cancer types where CETN2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CETN2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	−0.377	<.001	10	view →
HNSC	Male	All	−0.183	.001	6	view →
CCRCC	Female	All	−0.165	.006	4	view →
PDAC	All	III,IV	−0.300	.047	1	view →
LSCC	Female	All	−0.194	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CETN2–COAD

Open the COAD breakdown →